Hyperglycemia in patients treated with the pan-PI3K inhibitor buparlisib (BKM120): characterization, management, and assessment for pharmacodynamics

被引：0

作者：

Azaro, A. ^{[1
]}

Rodon, J. ^{[1
]}

Vansteenkiste, J. F. ^{[2
]}

Ando, Y. ^{[3
]}

Doi, T. ^{[4
]}

Mills, D. ^{[5
]}

Sarr, C. ^{[6
]}

Di Tomaso, E. ^{[7
]}

Massacesi, C. ^{[8
]}

Naumann, R. W. ^{[9
]}

机构：

[1] Vall dHebron Univ Hosp, Barcelona, Spain

[2] Univ Hosp Gasthuisberg, Resp Oncol Unit, B-3000 Louvain, Belgium

[3] Nagoya Univ Hosp, Dept Clin Oncol & Chemotherapy, Nagoya, Aichi, Japan

[4] Natl Canc Ctr Hosp, Gastrointestinal Oncol Div, Chiba, Japan

[5] Novartis Pharma AG, Stat, Basel, Switzerland

[6] Novartis Pharma AG, Modeling, Basel, Switzerland

[7] Novartis Inst Biomed Res, Cambridge, MA USA

[8] Novartis Oncol, Global Clin Program, Paris, France

[9] Carolinas Med Ctr, Div Gynecol Oncol, Charlotte, NC 28203 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

884

引用

页码：S186 / S186

页数：1

共 50 条

[41] The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo
Meier, Friedegund Elke
Niessner, Heike
Schmitz, Jennifer
Schmid, Andreas
Calaminus, Carsten
Pichler, Bernd
Forschner, Andrea
Flaherty, Keith
Honegger, Juergen Bernd
Dummer, Reinhard
Tabatabai, Ghazaleh
Weide, Benjamin
Eigentler, Thomas K.
Schadendorf, Dirk
Quintanilla-Fend, Leticia
Garbe, Claus
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[42] Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM)
Wen, Patrick Y.
Yung, W. K. Alfred
Mellinghoff, Ingo K.
Lamborn, Kathleen
Ramkissoon, Shakti
Cloughesy, Timothy Francis
Rinne, Mikael
Omuro, Antonio Marcilio Padula
DeAngelis, Lisa Marie
Gilbert, Mark R.
Chi, Andrew S.
Batchelor, Tracy
Colman, Howard
Chang, Susan Marina
Massacesi, Cristian
DiTomaso, Emmanuelle
Prados, Michael
Reardon, David A.
Ligon, Keith L.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[43] The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo
Niessner, H.
Forschner, A.
Schmitz, J.
Schmid, A.
Calaminus, C.
Sinnberg, T.
Tabatabai, G.
Quintanilla-Fend, L.
Pichler, B. J.
Garbe, C.
Meier, F.
EXPERIMENTAL DERMATOLOGY, 2014, 23 (03) : E43 - E43
[44] PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA: AN IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM STUDY
Wen, Patrick
Yung, Alfred
Mellinghoff, Ingo
Lamborn, Kathleen
Ramkissoon, Shakti
Cloughesy, Timothy
Rinne, Mikael
Omuro, Antonio
DeAngelis, Lisa
Gilbert, Mark
Chi, Andrew
Batchelor, Tracy
Colman, Howard
Chang, Susan
Nayak, Lakshmi
Massacesi, Cristian
DiTomaso, Emmanuelle
Prados, Michael
Reardon, David
Ligon, Keith
NEURO-ONCOLOGY, 2013, 15 : 134 - 134
[45] The PI3K Inhibitor BKM120 has Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo
Niessner, H.
Schmitz, J.
Schmid, A.
Calaminus, C.
Pichler, B. J.
Forschner, A.
Flaherty, K.
Honegger, J. B.
Dummer, R.
Tabatabai, G.
Quintanilla-Fend, L.
Garbe, C.
Meier, F.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 5 - 5
[46] The PI3K Specific Inhibitor BKM120 Results Effective and Synergizes With Ruxolitinib In Preclinical Models Of Myeloproliferative Neoplasms
Bartalucci, Niccolo
Bogani, Costanza
Martinelli, Serena
Mannarelli, Garmela
Villeval, Jean-Luc
Vannucchi, Alessandro M.
BLOOD, 2013, 122 (21)
[47] Transcriptomic Systems Biology Analyses with Buparlisib (BKM120) Pan PI3K Inhibition in Canine B Cell Lymphoma (BCL): Leveraging Comparative Oncology for Cancer Therapeutics and Biomarker Discovery
Dashnamoorthy, Ravi
Beheshti, Afshin
Cass, Sarah
Kritharis, Athena
Burgess, Kristine
London, Cheryl
Evens, Andrew M.
BLOOD, 2018, 132
[48] A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
Smyth, Lillian M.
Monson, Kelsey R.
Jhaveri, Komal
Drilon, Alexander
Li, Bob T.
Abida, Wassim
Iyer, Gopa
Gerecitano, John F.
Gounder, Mrinal
Harding, James J.
Voss, Martin H.
Makker, Vicky
Ho, Alan L.
Razavi, Pedram
Iasonos, Alexia
Bialer, Philip
Lacouture, Mario E.
Teitcher, Jerrold B.
Erinjeri, Joseph P.
Katabi, Nora
Fury, Matthew G.
Hyman, David M.
INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 742 - 750
[49] A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
Lillian M. Smyth
Kelsey R. Monson
Komal Jhaveri
Alexander Drilon
Bob T. Li
Wassim Abida
Gopa Iyer
John F. Gerecitano
Mrinal Gounder
James J. Harding
Martin H. Voss
Vicky Makker
Alan L. Ho
Pedram Razavi
Alexia Iasonos
Philip Bialer
Mario E. Lacouture
Jerrold B. Teitcher
Joseph P. Erinjeri
Nora Katabi
Matthew G. Fury
David M. Hyman
Investigational New Drugs, 2017, 35 : 742 - 750
[50] PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA CONDUCTED BY THE IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM
Wen, Patrick Y.
Wen, Patrick Y.
Yung, W. K. Alfred
Mellinghoff, Ingo K.
Ramkissoon, Shakti
Alexander, Brian
Rinne, Mikael
Colman, Howard
Omuro, Antonio M.
DeAngelis, Lisa M.
Gilbert, Mark R.
DeGroot, John
Cloughesy, Timothy F.
Lee, Eudocia Q.
Nayak, Lakshmi
Chi, Andrew S.
Batchelor, Tracy
Chang, Susan M.
Prados, Michael D.
Reardon, David A.
Ligon, Keith L.
NEURO-ONCOLOGY, 2014, 16

← 1 2 3 4 5 →